Agenda
9:30-10:00AM: Registration
10:00-11:30: Presentation and Q&A;

Is your small business on the brink of taking its innovative cancer research to the next level but is in need of early-stage technology financing? Learn about how your company may be eligible to tap into the financial resources and new funding opportunities available from the National Cancer Institute�s (NCI) Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) Programs. The SBIR and STTR Programs offer funding in nanotechnology, anti-cancer agents, biomarkers, proteomics, pharmacodynamics, and many more areas of interest to the NCI.

David Beylin from the NCI SBIR Development Center will discuss the diverse SBIR and STTR funding opportunities and offer tips for applying. SBIR Program has recently released exciting new funding opportunities:

� Contract Topics
The SBIR Program announced 23 new contract funding opportunities in a range of novel technology areas to help successfully finance and lead innovations to commercialization. The NCI SBIR Program solicits proposals for SBIR contracts once annually. As compared to grant funding opportunities, SBIR contract topics are focused in scope and require the completion of specific activities and deliverables. In order to catalyze targeted technology development in key need areas that will result in a commercial product, the NCI SBIR Program is moving more of its resources towards contracts. The SBIR and STTR Programs offer funding in nanotechnology, anti-cancer agents, biomarkers, proteomics, pharmacodynamics, and many more areas of interest to the NCI.

� SBIR Phase II Bridge Award
The new Phase II Bridge award is specifically designed to augment previously funded NIH-wide SBIR Phase II projects that require additional funding in order to achieve key technical and regulatory milestones along the path toward commercialization. Phase II Bridge Award applicants may request budgets up to $1 million in total costs per year and project periods up to three years (a total of $3 million over three years) from the NCI.

For more information about this NCI SBIR & STTR, please visit http://sbir.cancer.gov.

Speaker's Bio
David Beylin, Program Manager, SBIR Development Center, National Cancer Institute
David Beylin is a Program Manager with the SBIR Development Center at the National Cancer Institute, where he assists small businesses in the medical imaging field in securing government funding for innovative research and development projects with high commercial potential. David has over 10 years of experience in research, development and commercialization of scientific and medical instrumentation and molecular imaging agents. Previously, David was involved with X/Seed Capital Management, LLC, a seed-stage venture capital firm investing in breakthrough technologies. Prior to X/Seed, David worked for Naviscan PET Systems, Inc. in a variety of technical and management roles, including Vice President of Research, concentrating on the design, clinical validation, and regulatory clearance of high resolution Positron Emission Tomography devices and image-guided interventions. Mr. Beylin was trained in experimental nuclear physics at the Budker Institute of Nuclear Physics (Russia) and the KEK-High Energy Accelerator Research Organization (Japan). Mr. Beylin is certified in Nuclear Medicine Physics and Instrumentation by the American Board of Science in Nuclear Medicine.

Venue
The San Jose BioCenter
5941 Optical Court
San Jose, CA 95138
Click here for venue directions»